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Regarding “A comparative evaluation of
polytetrafluoroethylene, umbilical vein, and
saphenous vein bypass grafts for femoral-popliteal
above-knee revascularization: a prospective
randomized Department of Veterans Affairs
cooperative study”
To the Editors:
Johnson et al1 report the fourth published series of patients
requiring lower limb revascularization and undergoing a protocol
of prospective randomization to saphenous vein, umbilical vein,
or PTFE. Eickoff et al2 reported on 104 below-knee popliteal
procedures, Aalders and von Vroonhoven3 on 96 above-knee
popliteal bypasses, and McCollum et al4 on 191 patients with an
above-knee: below-knee ratio of 2:1. All of these data were accu-
mulated and, with the exception of the delayed report by Johnson
et al,1 reported in the 1980s. Several comments are in order:
1. Though these studies are dated and in many areas, flawed,
they are, nonetheless, incredibly, the only ones carried out
with more than one alternative to the saphenous vein, ran-
domized, prospective, and performed at multiple surgical
sites. This is in contradiction to the manuscript by Burger et
al,5 which typifies the usual reporting of lower limb graft
material reviews—a single graft compared with autologous
vein, the usual inferior results obtained with a prosthetic and
the standard conclusion that, despite differences in patency,
use of the prosthetic is “reasonable” and “acceptable.” The
Invited Comment by J. Mills,6 which should be required
reading for all vascular surgeons, points to the deficiencies of
statistical analysis in Burger’s paper1 and others based on
inadequate power.
2. The Meadox product used in all these studies is no longer
manufactured. The currently available UV graft is manufac-
tured by BioVascular Inc, Minn. There are available data7,8
showing absence of aneurysmal degradation with the latter
product as well as a significant reduction in the early throm-
botic events as documented by Johnson et al1 with the
Meadox product. This is based on improved quality control
during manufacture, reduction of residual aldehyde moities in
graft and storage media, and appreciation of the surgical skills
required for implantation. Our first decade of experience with
the UV graft was reported in 1988, not in 1998 (reference 20
in Johnson et al1). Additional experience and even better
results with the improved UV graft were reported in 19957
and 1996.8
3. Current evaluations of graft materials should include intraop-
erative completion duplex sonography and be complimented,
as required, with completion angiography. This is the only way
to establish the different materials and surgeons on an even
keel.
4. The ultimate test for comparative function of materials is in
the crural position. No such studies have been performed in
a multihospital, randomized prospective manner and with
more than one alternative material to the saphenous vein.
The Advisory Council for Vascular Surgery to the American
College of Surgeons has recently authorized the formulation
of such a protocol. Its execution will depend on availability
of funding from agencies, foundations, and industry.
Hopefully, this will occur and provide some needed guidance
in a field now clouded by personal bias and the industrial
complex.
Herbert Dardik, MD
Englewood Hospital and Medical Center
Englewood, NJ
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Reply
We welcome comments from the vascular community about
our recently published article on the comparative performance of
saphenous vein, PTFE, and HUV bypasses that were implanted
between 1983 and 1988 and followed until October 1991.1 Dr
Dardik is correct that the HUV bypasses were provided by
Meadox and not by BioVascular. We apologize for the incorrect
citation of his 1988 article (wrong year but correct volume of
Journal of Vascular Surgery).
We concur with Dr Mill’s2 and Dr Dardik’s comments that
the Burger report3 has inadequate “power” and inappropriately
suggests a similar vein and PTFE bypass performance (P = .065)
at 104 weeks’ follow-up (81% primary patency for vein as com-
pared with 67% for PTFE). Note that in our report,1 the 2-year
assisted primary patency was 80.7% in the vein group as compared
with 69.4% in the PTFE group, results that were very similar to
those of Burger but with more patients and longer follow up were
significantly different (P = .03).
The major question raised by Dr Dardik’s letter is whether a
new but similar randomized study needs to be performed in the
21st century with special postoperative duplex surveillance for
patency and aneurysmal formation. I certainly endorse such an
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effort and look forward to the long-term results, which will proba-
bly not be available for 5 to 7 years. Until then, one should consider
many factors, including the results of previously reported, well-
designed, randomized studies, when choosing a bypass conduit.
Willard C. Johnson, MD
Kelvin K. Lee, PhD
Palo Alto, Veterans Affairs Medical Center 
Palo Alto, Calif
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Regarding “Ambulatory venous pressure revisited”
To the Editors: 
I would like to comment on the paper by P. Neglen and S.
Raju, “Ambulatory venous pressure revisited,” published in June
2000 in your journal (J Vasc Surg 2000;31:1206-13).
Neglen and Raju simultaneously measured ambulatory
venous pressure in the popliteal and dorsal foot veins. They stated
that the pressure drop in the dorsal foot vein was more marked
than in the popliteal vein. They concluded that ambulatory dor-
sal venous pressure was not always accurate in detecting changes
in the pressure of the tibial and popliteal veins. Although the
behavior of the dorsal foot venous pressure may be normal, deep
venous pressure may decrease to a lesser degree or even increase.
Their statement merits some comment.
The measurements of Neglen and Raju showed, in reality,
that a pressure difference occurred between the popliteal and the
dorsal foot veins during activation of the muscle venous pump.
Höjensgard and Stürup in 19521 and Arnoldi in 19662 first
reported that the ambulatory pressure in the posterior tibial vein
decreased considerably during ambulation, whereas it did not
decline in the popliteal vein. They only noted this fact and did not
point out its implication for the venous circulation of the lower
extremity. In fact, the ambulatory pressure gradient occuring
between the femoral/popliteal vein and the veins beneath the
knee level plays an important role in the venous hemodynamics.
This issue is discussed in my recent paper.3 The pressure gradient
explains why the blood flows downward in the insufficient saphe-
nous vein and inward through the calf perforators during ambu-
lation.4 It explains, further, why the reflux can only take place in
an insufficient vein connecting the femoral, popliteal, or iliac vein
with one of the deep veins of the lower leg. Moreover, the pres-
sure gradient may be the trigger factor initiating neovasculariza-
tion. When high ligation of the saphenofemoral junction without
stripping of the insufficient saphenous stem is performed, the
insufficient saphenous trunk in the thigh remains patent in most
cases. Venous pressure measurements have shown that the low
ambulatory pressure extends from the deep veins of the lower leg
into the blind saphenous trunk in the thigh.3 This results in a
pressure gradient between the femoral vein and the blind saphe-
nous trunk and may initiate neovascularization, because the pres-
sure gradient is an important hemodynamic impetus to the
formation of collateral circulation.
Several authors have proved that the pressures in the superfi-
cial and deep veins of the lower leg are similar or almost identi-
cal.1, 2, 5-7 These veins form conjoined vessels due to numerous
communicating veins. The opinion expressed by Neglen and Raju
that the pressure changes in the superficial veins do not reflect
those in the deep veins of the lower leg is not substantiated. With
regard to the previously mentioned ambulatory pressure gradient,
it was not surprising that Neglen and Raju found an ambulatory
pressure difference between the popliteal and dorsal foot veins.
Cestmir Recek, MD
Vienna, Austria
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Reply
We have read with interest the comments of Dr Recek
regarding our article “Ambulatory venous pressure revisited (J
Vasc Surg 2000;31:1206-13). His comments include a criticism
of our interpretation of the data as presented in the paper as well
a synopsis of his own hypothesis regarding the origin of saphe-
nous reflux and neovascularization. The latter subjects were not
covered in our article, but we are able to respond to specific crit-
icisms of the material presented in our manuscript.
The major thrust of his criticism appears to be that we have
only described a “difference” in pressures between the dorsal vein
and the popliteal vein, a fact already known (Höjensgard and
Stürup 1952, Arnoldi 1966), and thus nothing new. Dr Recek
further asserts that, contrary to our interpretation, “several
authors have proved that the pressures in the superficial and deep
veins of the lower leg are similar or almost identical” because of
equilibration from the presence of numerous communicating
veins. This criticism appears to be based on an inaccurate and/or
incomplete reading of our data (Table I, page 1209) and our
interpretation of it, as detailed in the article. We identified three
categories of patients in whom the popliteal pressure respectively
decreased markedly (group A), decreased marginally (group B),
and increased (Group C) in response to calf exercise. Yet in all
three groups the dorsal vein pressure decreased markedly in simi-
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